pharma · HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER · Advanced HER2-Expressing Solid Tumors. · BOLT
Bolt Biotherapeutics
Bolt Biotherapeutics clinical programs — 0 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Redwood City, USA HQ
2015 Founded
51 Employees
Public company Type
BOLT · NYSE Ticker
Company details
- Status
- Public
- HQ
- Redwood City, USA
- Founded
- 2015
- Employees
- 51
- Programs
- 6
- Drugs
- 4
- Patents
- 7
Bolt Biotherapeutics projects
0 ClinicalTrials.gov programs sponsored by Bolt Biotherapeutics.
Bolt Biotherapeutics has 0 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
No programs matched
Frequently asked questions
How many clinical projects does Bolt Biotherapeutics have?
0 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.